|
Re: Dr. Dennis Slamon, "our hero"
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626365/
I was reading in this Chinese study Herceptin reduced recurrence by:
In the present study, in multivariate analysis by 3-DFS this study showed a 68.6% reduction in risk of recurrence (hazard ratio, 0.314; 95% confidence interval, 0.159–0.619; P = 0.001) in the HER2-positive patients who received trastuzumab treatment when compared with the HER2-positive patients who did not receive trastuzumab treatment. This finding was consistent with the 30%–50% relative risk reduction of recurrence and death previously found in large randomized clinical trials such as BCIRG 006, HERA.
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes
Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"
Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla
Reconstruction: TRAM flap, partial loss, Revision
The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
|